National Cancer Institute Thesaurus

Last uploaded: August 27, 2019
Preferred Name

Brentuximab Vedotin

Synonyms

Adcetris

Anti-CD30 Monoclonal Antibody-MMAE SGN-35

Anti-CD30 Antibody-Drug Conjugate SGN-35

SGN-35

Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35

cAC10-vcMMAE

ADC SGN-35

Brentuximab Vedotin

BRENTUXIMAB VEDOTIN

Definitions

An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.

ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C66944

Accepted_Therapeutic_Use_For

Hodgkin lymphoma (HL); anaplastic large cell lymphoma (ALCL); other CD30-expressing peripheral T-cell lymphomas

CAS_Registry

914088-09-8

Chemical_Formula

C68H106N11O15S

code

C66944

Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

Contributing_Source

CTRP

FDA

DEFINITION

An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.

Display_Name

Brentuximab Vedotin

FDA_UNII_Code

7XL5ISS668

FULL_SYN

Adcetris

Anti-CD30 Monoclonal Antibody-MMAE SGN-35

Anti-CD30 Antibody-Drug Conjugate SGN-35

SGN-35

Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35

cAC10-vcMMAE

ADC SGN-35

Brentuximab Vedotin

BRENTUXIMAB VEDOTIN

Has_Target

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C38906

label

Brentuximab Vedotin

Legacy_Concept_Name

SGN-35

PDQ_Closed_Trial_Search_ID

530758

PDQ_Open_Trial_Search_ID

530758

Preferred_Name

Brentuximab Vedotin

prefixIRI

ncit:C66944

Semantic_Type

Pharmacologic Substance

UMLS_CUI

C2932409

subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158973

Delete Subject Author Type Created
No notes to display
Create New Mapping

Delete Mapping To Ontology Source
http://purl.bioontology.org/ontology/MESH/C547738 MESH LOOM
http://purl.obolibrary.org/obo/dinto_DB08870 DINTO LOOM
http://purl.bioontology.org/ontology/RXNORM/1147320 RXNORM LOOM
http://purl.bioontology.org/ontology/PDQ/CDR0000530758 PDQ LOOM
http://purl.bioontology.org/ontology/NDFRT/N0000183555 NDFRT LOOM
http://purl.obolibrary.org/obo/DRON_00020132 DRON LOOM
http://purl.bioontology.org/ontology/SNOMEDCT/713395006 SNOMEDCT LOOM
http://purl.bioontology.org/ontology/UATC/L01XC12 ATC LOOM
http://purl.bioontology.org/ontology/VANDF/4031047 VANDF LOOM
http://purl.bioontology.org/ontology/NDDF/013904 NDDF LOOM
http://purl.jp/bio/4/id/201206090882884997 IOBC LOOM